Jul 30, 2008
The drug uses a material called methylthioninium chloride to prevent the accumulation of a protein associated with brain cell death. The drug went through initial human trials and showed an 81% decline in the disease's progression.
It is scheduled for wider trials in 2009 and is planned for production in 2012 if all goes well.
Here's the BBC article: http://news.bbc.co.uk/2/hi/health/7525115.stm